Our Research Projects

These models allow us to recreate the tumor microenvironment with high fidelity, enabling us to observe cellular interactions and behaviors that are critical for understanding cancer progression. By studying these organoids, we can uncover the mechanisms behind tumor heterogeneity and the varied responses to treatments among patients. This insight is vital for developing targeted therapies that address the unique characteristics of each tumor.
Additionally, we are exploring the integration of high-throughput screening technologies with our organoid models, which will significantly accelerate the drug discovery process. By systematically testing a wide range of compounds, we can identify those that exhibit the most promising efficacy against specific tumor types, paving the way for clinical trials tailored to the individual patient's cancer profile.

3D Organoid platforms to study anti-invasive therapy :

3D Organoid models representing different stages of GBM :

Growing organoids in distinct environment :

Through the development of these targeted nanosystems, we are also exploring the potential of stimuli-responsive nanocarriers, which release drugs in response to specific environmental triggers, such as pH or enzyme levels within tumors. Additionally, we are investigating how nanoparticle engineering can enhance the delivery of combination therapies, optimizing the synergy between drugs and making treatment even more effective. By focusing on precision and safety, our work in nanotherapeutics aims to set new standards in personalized cancer care and treatment efficacy.

The accompanying images highlight some of the advanced techniques and outcomes of our research:
1.Nanostructure Imaging: The electron microscopy images on the left showcase the intricate nanostructures in injectable gel system developed in our lab. These structures are engineered to provide optimal stability and drug encapsulation efficiency, ensuring controlled and targeted release. Through this patented technology, we aim to provide minimally invasive and cost affordable treatment against high-grade gliomas.
2.Blood-Brain Barrier Delivery: The middle and right panels illustrate our success in achieving drug delivery across the blood-brain barrier (BBB), a significant challenge in treating brain cancers. Using specially formulated nanoplatforms, we've demonstrated that our system can effectively cross the BBB and deliver therapeutic agents directly to the brain, as seen in the imaging studies one hour post-injection (1h PI). The NIR image scan indicates high levels of nanocarrier accumulation in the targeted brain tumor regions, confirming the efficacy of our delivery approach.
3.Injectable system: Our patented lipid nanovesicle in gel system, shown in the image, represents a breakthrough in localized delivery for sustained release. By embedding these nanovesicles within a tunable gel matrix, we can enhance their regional delivery potential and minimize off-target tissue damage.

Our research focuses on understanding the mechanisms by which nanoparticles can improve the delivery and efficacy of immune-modulating agents. By leveraging the unique properties of nanoparticles, we aim to enhance the uptake of therapeutic agents by immune cells, thereby amplifying the immune response against tumors. We are particularly interested in developing targeted nanovaccines that can stimulate the immune system to recognize and attack cancer cells while minimizing side effects.
In addition to our work on nanoparticles, we are exploring the role of the tumor microenvironment in shaping immune responses. By characterizing the immune landscape within tumors, we aim to identify key factors that promote or inhibit effective antitumor immunity. Our studies include the evaluation of various immune cell populations, such as T cells, dendritic cells, and macrophages, to understand their interactions with tumor cells and the impact of therapeutic interventions

By employing PDX models, which involve implanting human tumors directly into the corresponding organ of immunocompromised mice, we can maintain the heterogeneity and complexity of the original tumor. This approach allows for a more accurate assessment of how specific therapies interact with tumor biology, leading to more personalized treatment strategies. In parallel, the use of immunocompetent mouse models helps us understand how an intact immune system interacts with tumor cells and therapeutic interventions.

Syngeneic mouse model development for GBM :